Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to -$1.8 million.

  • RxSight's Free Cash Flow fell 29028.7% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 1831.36%. This contributed to the annual value of -$22.4 million for FY2024, which is 5176.16% up from last year.
  • Per RxSight's latest filing, its Free Cash Flow stood at -$1.8 million for Q3 2025, which was down 29028.7% from -$5.9 million recorded in Q2 2025.
  • RxSight's 5-year Free Cash Flow high stood at -$453000.0 for Q3 2024, and its period low was -$18.5 million during Q1 2023.
  • Its 5-year average for Free Cash Flow is -$10.2 million, with a median of -$9.9 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first soared by 9475.39% in 2024, then crashed by 29028.7% in 2025.
  • Quarter analysis of 5 years shows RxSight's Free Cash Flow stood at -$9.1 million in 2021, then tumbled by 56.44% to -$14.2 million in 2022, then skyrocketed by 30.42% to -$9.9 million in 2023, then surged by 48.37% to -$5.1 million in 2024, then surged by 65.38% to -$1.8 million in 2025.
  • Its Free Cash Flow stands at -$1.8 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$9.4 million for Q1 2025.